share_log

Aditxt | CORRESP: CORRESP

Aditxt | CORRESP: CORRESP

Aditxt | CORRESP：信函
美股SEC公告 ·  2024/06/22 10:17

Moomoo AI 已提取核心訊息

Aditxt, Inc., a biotech company, has responded to a comment from the U.S. Securities and Exchange Commission (SEC) regarding its Revised Preliminary Proxy Statement filed on June 18, 2024. The SEC's inquiry pertained to the relationship between the Exchange Agreement and the Merger Agreement that Aditxt entered into in December 2023. Aditxt clarified that the Exchange Agreement, which closed on December 22, 2023, is independent of the Merger Agreement's ongoing and uncertain transactions. The company has already issued Series A-1 Convertible Preferred Stock and fulfilled its obligations under the Exchange Agreement, which are not contingent on the Merger Agreement's completion. Aditxt has amended its Form 8-K to reflect this clarification and acknowledges the need to file a separate proxy statement for stockholder approval if the Merger Agreement proceeds.
Aditxt, Inc., a biotech company, has responded to a comment from the U.S. Securities and Exchange Commission (SEC) regarding its Revised Preliminary Proxy Statement filed on June 18, 2024. The SEC's inquiry pertained to the relationship between the Exchange Agreement and the Merger Agreement that Aditxt entered into in December 2023. Aditxt clarified that the Exchange Agreement, which closed on December 22, 2023, is independent of the Merger Agreement's ongoing and uncertain transactions. The company has already issued Series A-1 Convertible Preferred Stock and fulfilled its obligations under the Exchange Agreement, which are not contingent on the Merger Agreement's completion. Aditxt has amended its Form 8-K to reflect this clarification and acknowledges the need to file a separate proxy statement for stockholder approval if the Merger Agreement proceeds.
生物技術公司aditxt已針對其於2024年6月18日提交的修訂後初步代理聲明，回應了美國證監會（SEC）的一份評論。 SEC的調查涉及aditxt在2023年12月簽訂的交易協議和併購協議之間的關係。 aditxt澄清，於2023年12月22日關閉的交易協議獨立於併購協議正在進行中的不確定交易。公司已發行A-1系列可轉換優先股，並履行了交易協議下的義務，這些義務不以併購協議的完成爲前提。 aditxt已修改其8-k表格以反映此澄清，並承認需要爲股東批准單獨提出代理聲明，如果併購協議繼續進行。
生物技術公司aditxt已針對其於2024年6月18日提交的修訂後初步代理聲明，回應了美國證監會（SEC）的一份評論。 SEC的調查涉及aditxt在2023年12月簽訂的交易協議和併購協議之間的關係。 aditxt澄清，於2023年12月22日關閉的交易協議獨立於併購協議正在進行中的不確定交易。公司已發行A-1系列可轉換優先股，並履行了交易協議下的義務，這些義務不以併購協議的完成爲前提。 aditxt已修改其8-k表格以反映此澄清，並承認需要爲股東批准單獨提出代理聲明，如果併購協議繼續進行。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Evaxion Biotech
    EVAX
    -- 6.030
    PMGC Holdings
    ELAB
    -- 3.100
    Lantern Pharma
    LTRN
    -- 5.400
    Transcode Therapeutics
    RNAZ
    -- 7.040
    Neuphoria Therapeutics
    NEUP
    -- 4.390
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    1月議息會議來襲！美聯儲暫停降息已成定局？
    🎙️討論 1. 美聯儲是否如期按下降息“暫停鍵”？ 2. 你覺得特朗普總統的政治舉措會改變美聯儲的立場嗎？ 3. 你會如何調整你的持倉配置？ 展开
    這是十二月CPI的分析，以一張圖表呈現